Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 21
Filtrar
Mais filtros

Bases de dados
País/Região como assunto
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Horm Res ; 71(4): 228-36, 2009.
Artigo em Inglês | MEDLINE | ID: mdl-19258715

RESUMO

BACKGROUND/AIMS: The aim of the study was to evaluate the efficacy and safety of lanreotide prolonged release (PR) 30 mg (long-acting lanreotide) in girls with constitutional tall stature (CTS). METHODS: This open label prospective study included 35 girls (mean age 12.6 years) with CTS and a predicted adult height of >180 cm. Intramuscular injections of lanreotide PR 30 mg were given every 14 days, for a minimum of 12 months and up to 36 months. Adult height was compared with pretreatment predicted height. RESULTS: The mean predicted adult height was reduced by 3.8 cm (95% CI 3.7-4.9 cm) in the restricted intent-to-treat population. Mean growth velocity decreased from 7.9 +/- 1.5 cm/year at preinclusion to 1.7 +/- 2.3 cm/year at the last visit on treatment (n = 35). Gastrointestinal adverse events and cholelithiasis were reported in 35/37 patients and 5/37 patients, respectively. There was 1 withdrawal due to gastrointestinal disorders. CONCLUSIONS: Biweekly intramuscular lanreotide PR 30 mg given to girls with CTS after the onset of pubertal development reduced adult height as compared with predicted height. Treatment-associated adverse events were consistent with the overall safety profile of lanreotide 30 mg PR and did not deter most patients from long-term treatment.


Assuntos
Peptídeos Cíclicos/uso terapêutico , Somatostatina/análogos & derivados , Adolescente , Estatura/efeitos dos fármacos , Preparações de Ação Retardada/uso terapêutico , Feminino , Transtornos do Crescimento/tratamento farmacológico , Humanos , Peptídeos Cíclicos/efeitos adversos , Estudos Prospectivos , Somatostatina/efeitos adversos , Somatostatina/uso terapêutico
2.
J Clin Endocrinol Metab ; 91(8): 2972-9, 2006 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-16720662

RESUMO

CONTEXT: Pediatric management of patients with Turner syndrome focuses on height, frequently resulting in a delay of pubertal induction. The influence of pubertal management on psychosocial adjustment and sex life has not been evaluated in Turner syndrome patients. OBJECTIVE: The objective of the study was to identify the determinants of self-esteem, social adjustment, and initiation of sex life in patients with Turner syndrome, particularly those related to pubertal management. DESIGN: This was a prospective evaluation, the StaTur study. SETTING: The study was conducted with a population-based registry of GH-treated patients. PARTICIPANTS: Participants included 566 young adult women with Turner syndrome, aged 22.6 +/- 2.6 yr (range, 18.3-31.2). MAIN OUTCOME MEASURES: Measures used in the study were Coopersmith's Self-Esteem Inventory, Social Adjustment Scale Self-Report, questions on sexual experience, and extensive data on pediatric management. RESULTS: Low self-esteem was associated with otological involvement and limited sexual experience. Low social adjustment was associated with lower paternal socioeconomic class and an absence of sexual experience. Late age at first kiss or date was associated with cardiac involvement and a lack of spontaneous pubertal development. Age at first sexual intercourse was related to age at puberty and paternal socioeconomic class. Delayed induction of puberty had a long-lasting effect on sex life. Height and height gain due to GH treatment had no effect on outcomes. CONCLUSIONS: Puberty should be induced at a physiologically appropriate age in patients with Turner syndrome to optimize self-esteem, social adjustment, and initiation of the patient's sex life. Therapeutic interventions altering normal pubertal development in other groups of patients should be reconsidered in light of these findings.


Assuntos
Puberdade/fisiologia , Autoimagem , Comportamento Sexual , Ajustamento Social , Síndrome de Turner/psicologia , Adolescente , Adulto , Fatores Etários , Análise de Variância , Estatura , Índice de Massa Corporal , Coito , Feminino , Humanos , Menarca , Puberdade/psicologia , Sexualidade/fisiologia , Sexualidade/psicologia , Fatores Socioeconômicos , Inquéritos e Questionários , Síndrome de Turner/terapia
3.
J Clin Endocrinol Metab ; 90(1): 147-51, 2005 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-15522928

RESUMO

Familial male-limited precocious puberty is a rare cause of precocious puberty due to activating mutations of the LH receptor, leading to early onset virilization and short stature. Two therapeutic approaches have been proposed: the P450 cytochrome inhibitor ketoconazole or combined treatment with spironolactone and testolactone. Results on adult heights have not been reported to date after these two treatments, and in this study we present results from five patients treated with ketoconazole at a median dose of 16.2 mg/kg.d for a median of 6.2 yr. Adult height was 173 cm (median; interquartile range, 14), similar to target height (175 cm; interquartile range, 9) and significantly higher than pretreatment predicted height (165 cm; interquartile range, 12; P < 0.01). During treatment, 39 of 58 (68%) testosterone measurements were less than 0.5 ng/ml (1.7 nmol/liter), nine of 58 (15%) were between 0.5 and 1 ng/ml (3.5 nmol/liter), and 10 of 58 (17%) were above 1 ng/ml. We observed a physiological increase in GnRH-stimulated LH levels after the age of 10 yr, and none of the patients had early activation of the gonadotropic axis. Liver tolerance was excellent, and only one patient had a transient and modest increase in serum transaminases. We conclude that ketoconazole is an efficient and well tolerated long-term treatment of familial male-limited precocious puberty that should be proposed as a first line therapy.


Assuntos
Estatura , Cetoconazol/uso terapêutico , Puberdade Precoce/tratamento farmacológico , Adulto , Determinação da Idade pelo Esqueleto , Criança , Pré-Escolar , Seguimentos , Humanos , Hormônio Luteinizante/sangue , Masculino , Puberdade Precoce/genética , Puberdade Precoce/fisiopatologia
4.
J Clin Endocrinol Metab ; 90(9): 5197-204, 2005 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-15998771

RESUMO

OBJECTIVE: The objective of this study was to evaluate factors affecting adult height (AH) in patients with Turner syndrome treated with GH. DESIGN: The study design was a population-based cohort study. SETTING: The setting was The StaTur Study, a register of patients treated in France between 1986 and 1997, followed for a mean of 9.3 yr. PATIENTS: We followed 704 of the 891 eligible patients (79%) to AH. INTERVENTION: GH (0.8 +/- 0.2 IU/kg.wk; 0.26 +/- 0.06 mg/kg.wk; mean +/- sd) was administered for 5.0 +/- 2.2 yr. Puberty was classified as spontaneous (10%), spontaneous with secondary estrogens (13%), or induced (77%). Estrogen treatment was initiated at 15.0 +/- 1.9 yr of age in those with induced puberty. MAIN OUTCOME MEASURE: The main outcome measure was multivariate analysis of AH after grouping potential predictors. RESULTS: The mean AH was 149.9 +/- 6.1 cm, 8.5 cm above projected height. The model explained 90% of the variance, with major effects of age at initiation and duration of treatment. Other factors included birth length, target height, bone age delay and weight at initiation of treatment, age at pubertal onset, GH dose, and number of injections per week. Age at introduction of estrogens was not a predictor, and the use of percutaneous vs. oral estrogens was associated with greater height (+2.1 cm; 95% confidence interval, 1.00-3.25). CONCLUSIONS: Our results support the early initiation of GH treatment and induction of puberty at a physiological age to achieve optimal AH. They suggest that GH should be injected daily, and percutaneous estrogens used. These results should be considered in the context of the lack of demonstrable influence of AH on psycho-social outcomes, uncertainties regarding long-term safety, and treatment cost.


Assuntos
Estatura , Hormônio do Crescimento Humano/uso terapêutico , Puberdade , Síndrome de Turner/tratamento farmacológico , Síndrome de Turner/fisiopatologia , Adolescente , Criança , Estudos de Coortes , Esquema de Medicação , Estrogênios/uso terapêutico , Feminino , Crescimento/efeitos dos fármacos , Hormônio do Crescimento Humano/administração & dosagem , Humanos , Injeções , Modelos Biológicos , Análise Multivariada
5.
J Clin Endocrinol Metab ; 90(4): 1992-7, 2005 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-15644402

RESUMO

GH is used to increase adult height in children with Turner's syndrome with little knowledge of the impact on quality of life. We carried out a population-based cohort study of quality-of-life determinants in young women with Turner's syndrome, all previously treated with GH. Of 891 eligible women aged over 18 yr and recorded in the French Growth Hormone Register, 818 were available and 568 participated (69%). They were assessed for demographic characteristics, health status, sexual life, treatment expectations, scores for Medical Outcome Study Short Form 36 (SF-36), and General Health Questionnaire 12. Participants were 22.6 +/- 2.6 yr old (mean +/- sd), measured 150.9 +/- 5.6 cm, and had received GH for 4.8 +/- 2.2 yr. SF-36 scores were similar in participants and French women of the general population. Cardiac (12% of participants) or otological (26% of participants) involvement or induction of puberty after 15 yr of age was associated with lower scores for at least one of the SF-36 dimensions. Height and estimated height gain from treatment were not associated with quality-of-life scores. Higher expectations from treatment were associated with lower quality of life. We conclude that quality of life is normal and unaffected by height in young adults with Turner's syndrome treated with GH. These data emphasize the need to give appropriate attention to general health and otological care rather than focus on stature in the care of children with Turner's syndrome.


Assuntos
Hormônio do Crescimento/uso terapêutico , Qualidade de Vida , Síndrome de Turner/psicologia , Adolescente , Criança , Estudos de Coortes , Feminino , Nível de Saúde , Humanos , Síndrome de Turner/tratamento farmacológico
6.
J Clin Endocrinol Metab ; 88(4): 1587-93, 2003 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-12679443

RESUMO

The efficacy of GH for increasing adult height (AH) in short adolescents born small for gestational age (SGA) is unclear, due to the lack of long-term controlled trials. A total of 168 short children born SGA (age, 10.5 yr for girls and 12.5 yr for boys) were randomly assigned to receive either 0.067 mg/kg.d GH until attainment of AH or no treatment. In this per-protocol analysis, 91 of 102 patients in the treated group and 33 of 47 patients in the control group were followed to AH. Mean height at inclusion was -3.2 SD score (SDS). Treatment duration was 2.7 +/- 0.6 yr. AH was -2.7 +/- 0.9 and -2.1 +/- 1.0 SDS in the control and treated groups, respectively (P < 0.005). The groups differed by 0.6 SDS units (95% confidence interval, 0.2-0.9). Height gain was 0.5 +/- 0.8 and 1.1 +/- 0.9 SDS in the control and treated groups, respectively (P = 0.002). Multivariate analyses confirmed the independent effects of treatment (0.6 SDS) and treatment duration (0.4 SDS/yr). All potential biases would tend to decrease the estimate of the treatment effect. Treatment tolerance was excellent. We concluded that the potential for spontaneous catch-up in short adolescents born SGA is limited. GH treatment increases AH by at least 0.6 SDS in this population.


Assuntos
Estatura , Hormônio do Crescimento Humano/uso terapêutico , Recém-Nascido Pequeno para a Idade Gestacional , Adolescente , Criança , Feminino , Hormônio do Crescimento Humano/efeitos adversos , Humanos , Recém-Nascido , Fator de Crescimento Insulin-Like I/análise , Masculino , Fatores de Tempo , Resultado do Tratamento
7.
J Clin Endocrinol Metab ; 87(9): 4111-6, 2002 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-12213857

RESUMO

Depot GnRH agonists are widely used for the treatment of precocious puberty. Leuprorelin 3-month depot is currently used in adults but has not been evaluated in children. We evaluated the efficacy of this new formulation (11.25 mg every 3 months), for the suppression of gonadotropic activation and pubertal signs in children with central precocious puberty. We included 44 children (40 girls) with early-onset pubertal development in a 6-month open trial. The inclusion criteria were clinical pubertal development before the age of 8 (girls) or 10 (boys), advanced bone age, enlarged uterus (>36 mm), testosterone more than 1.7 nmol/liter (boys), and pubertal response of LH to GnRH (peak >5 IU/liter). The principal criterion for efficacy assessment, GnRH-stimulated LH peak less than 3 IU/liter, was met in 81 of 85 (95%) of the tests performed at months 3 and 6. The remaining four values were slightly above the threshold. The levels of sex steroids were also significantly reduced and clinical pubertal development was arrested. Plasma leuprorelin levels, measured every 30 d, were essentially stable after d 60. Local intolerance was noted after 10 of 86 injections (12%), and was mild in four cases, moderate in five cases, and severe in one. Among these 10 events, 4 consisted in local pain at injection's site. In conclusion, leuprorelin 3-month depot efficiently inhibits the gonadotropic axis in 95% of children with central precocious puberty studied for a 6-month period. This regimen allows the reduction of the number of yearly injections from 12 to 4.


Assuntos
Leuprolida/uso terapêutico , Puberdade Precoce/tratamento farmacológico , Criança , Preparações de Ação Retardada , Estradiol/sangue , Feminino , Hormônio Foliculoestimulante/sangue , Hormônio Liberador de Gonadotropina/sangue , Humanos , Injeções Subcutâneas , Leuprolida/administração & dosagem , Hormônio Luteinizante/sangue , Masculino , Puberdade Precoce/sangue , Testosterona/sangue , Fatores de Tempo
8.
J Clin Endocrinol Metab ; 87(1): 29-32, 2002 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-11788616

RESUMO

Androgen insensitivity syndromes (AIS) result from the incapacity for T and dihydrotestosterone to virilize male embryos and is mainly attributable to molecular defects of the AR gene. In normal males, T and LH rise during the first few months of life, and this physiological surge is commonly used to evaluate the gonadotropic axis at this age. This neonatal surge has not been evaluated in detail in newborns with AIS. We sequentially measured plasma T, LH, and FSH during the first 3 months of life in 15 neonates with AIS and AR mutation. A GnRH and an human CG stimulation test were also performed. Patients were divided in 2 groups with complete (n = 10) or partial (n = 5) AIS (CAIS or PAIS), based on the clinical phenotype. In patients with PAIS, T levels were in the high-normal range at d 30 (18.4 +/- 6.9 nM) and d 60 (12.8 +/- 3.8 nM). In contrast, plasma T values were below the normal range in 9 of 10 patients with CAIS at d 30 (1 +/- 0.3 nM) and d 60 (1.4 +/- 0.7 nM, both P < 0.004 vs. PAIS). Plasma LH values were low in CAIS at d 30 (0.7 +/- 0.1U/liter) and increased normally in PAIS (8.7 +/- 2.5 U/liter, P = 0.004). We conclude that the postnatal T and LH surge occurs expectedly in neonates with PAIS but is absent in those with CAIS and that the postnatal T rise requires the receptivity of the hypothalamo-pituitary axis to T.


Assuntos
Síndrome de Resistência a Andrógenos/metabolismo , Síndrome de Resistência a Andrógenos/sangue , Síndrome de Resistência a Andrógenos/genética , Feminino , Hormônio Foliculoestimulante/sangue , Humanos , Lactente , Recém-Nascido , Hormônio Luteinizante/sangue , Masculino , Testosterona/sangue , Fatores de Tempo
9.
Bull Acad Natl Med ; 186(7): 1211-6; discussion 1216-9, 2002.
Artigo em Francês | MEDLINE | ID: mdl-12669662

RESUMO

The history of growth hormone treatments in France has been marked by the tragedy of the epidemy of Creutzfeld-Jakob disease secondary to the contamination of preparations of extractive growth hormone, administered between 1983 and 1985. The substitution with biosynthetic growth hormone has suppressed this risk and allow the analysis of long term results. It is still too early to evaluate the efficacy in short stature secondary to chronic renal insufficiency and intrauterine growth retardation. In contrast, final heights are actually known in patients with growth hormone deficiency and Turner Syndrome. These adult heights, ranging around--2 SDS of the normal population, are satisfaisant but not sufficient, pointing out the necessity of an optimization of the treatments. Earlier onset of therapy, best adaptation and increase of the doses are some of the possibilities.


Assuntos
Transtornos do Crescimento/tratamento farmacológico , Hormônio do Crescimento/uso terapêutico , Criança , Humanos
11.
Horm Res ; 65(3): 126-31, 2006.
Artigo em Inglês | MEDLINE | ID: mdl-16491011

RESUMO

BACKGROUND: Androgen receptor defects affect the regulation of the gonadotropic axis. However, little is known about the timing of pubertal maturation in complete androgen insensitivity syndrome (CAIS). AIMS: To evaluate growth, skeletal maturation and gonadotropin and sex steroid secretion in patients with CAIS and intact gonads at puberty. METHODS: Clinical, auxological and hormonal evaluation of 9 patients with CAIS from birth up to 17 years of age, prior to gonadectomy, in a single institution, retrospective study. RESULTS: Breast development occurred at a median age of 11.1 years, thumb sesamoid appeared at 11.5 years, and peak height velocity at 12.3 years, all consistent with average female values. However, median adult male height (+1.2 SDS) was closer to the patients' male target height (-0.3 SDS). Plasma testosterone levels rose early compared to normal boys. LH (basal and GnRH-stimulated) increased rapidly, above normal male values, in early puberty. CONCLUSIONS: This retrospective evaluation of a limited number of cases with a heterogeneous pattern of follow-up suggests that patients with CAIS may enter puberty at an age closer to female standards. These results imply a major role of direct androgen action, in utero or in early life, in determining the pattern of pubertal gonadotropin maturation.


Assuntos
Síndrome de Resistência a Andrógenos/fisiopatologia , Androgênios/fisiologia , Puberdade , Receptores Androgênicos/fisiologia , Adolescente , Envelhecimento , Síndrome de Resistência a Andrógenos/sangue , Estatura , Criança , Pré-Escolar , Estradiol/sangue , Estradiol/fisiologia , Hormônio Foliculoestimulante/sangue , Hormônio Foliculoestimulante/fisiologia , Humanos , Lactente , Recém-Nascido , Hormônio Luteinizante/sangue , Hormônio Luteinizante/fisiologia , Masculino , Mutação , Receptores Androgênicos/genética , Estudos Retrospectivos , Testosterona/sangue , Testosterona/fisiologia
12.
J Pediatr ; 146(1): 45-53, 2005 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-15644821

RESUMO

OBJECTIVES: To investigate in an open-label randomized study, the effect of two doses of growth hormone (GH) on final height and height velocity during the first 2 years of treatment of children with idiopathic short stature (mean baseline height standard deviation score [SDS] -3.2). STUDY DESIGN: Patients were treated with GH at 0.24 mg/kg/week, 0.24 mg/kg/week for the first year and at 0.37 mg/kg/week thereafter (0.24-->0.37), or 0.37 mg/kg/week. Final height was evaluated in 50 patients at study completion (mean treatment duration, 6.5 years). RESULTS: Patients who received 0.37 mg/kg/week (n = 72) experienced a significantly greater increase in height velocity than those who received 0.24 mg/kg/week (n = 70) (treatment difference = 0.8 cm/year; P = .003) or 0.24-->0.37 mg/kg/week (n = 67) (treatment difference = 0.9 cm/year; P = .001). For the 50 patients for whom final height measurements were available, mean height SDS increased by 1.55, 1.52, and 1.85 SDS, respectively, for the three dose groups. For the primary comparison between the 0.37 mg/kg/week and 0.24 mg/kg/week dose groups, the mean treatment difference (adjusted for differences in baseline predicted height SDS) was 0.57 SDS (3.6 cm; P = .025). Mean overall height gains (final height minus baseline predicted height) were 7.2 cm and 5.4 cm for the 0.37 mg/kg/week and 0.24 mg/kg/week dose groups, respectively, without dose effects on safety parameters. Final height measurements were within the normal adult height range for 94% of patients randomized to 0.37 mg/kg/week who continued to final height. CONCLUSION: GH treatment dose-dependently increases height velocity and final height in children with idiopathic short stature.


Assuntos
Estatura/efeitos dos fármacos , Transtornos do Crescimento/tratamento farmacológico , Hormônio do Crescimento Humano/administração & dosagem , Adolescente , Determinação da Idade pelo Esqueleto , Desenvolvimento Ósseo/efeitos dos fármacos , Criança , Relação Dose-Resposta a Droga , Feminino , Seguimentos , Humanos , Masculino , Proteínas Recombinantes/administração & dosagem , Fatores de Tempo , Resultado do Tratamento
13.
Horm Res ; 60(Suppl 1): 10-7, 2003.
Artigo em Inglês | MEDLINE | ID: mdl-12955012

RESUMO

Growth hormone (GH) deficiency is a rare disease in very young children and a challenge to the physician in terms of clinical recognition, diagnosis and treatment. Here, we review the available information regarding substitution of GH and other pituitary hormones in this patient group. Our results confirm the severity of the clinical presentation and the rapid loss of height (measured in standard deviation scores) in hypopituitary patients that occurs early in life. GH therapy induces a rapid catch-up of growth and the frequency of injections appears to be a more important determinant than the size of the dose itself. Long-term results are available in only a small percentage of patients, yet they show a favourable auxological outcome, compared with target height or historical height data from patients with severe hypopituitarism. In conclusion, although tremendous progress has been made in providing for those children with early onset and severe hypopituitarism, there is still a long way to go before we can claim that we have completely normalized their condition. In particular, careful assessments of the psychological and neurodevelopmental outcomes will become necessary in order to evaluate the 'final results' of endocrine replacement therapies.


Assuntos
Hormônio do Crescimento Humano/deficiência , Hipopituitarismo/tratamento farmacológico , Pré-Escolar , Hormônio do Crescimento/uso terapêutico , Hormônio do Crescimento Humano/metabolismo , Humanos , Lactente , Fator de Crescimento Insulin-Like I/metabolismo , Resultado do Tratamento
14.
Horm Res ; 58(3): 105-14, 2002.
Artigo em Inglês | MEDLINE | ID: mdl-12218375

RESUMO

OBJECTIVES: The precise evaluation of adolescent growth spurt is necessary for numerous clinical research studies of growth disorders and treatments. The objectives of our study were: (1) to evaluate the reliability of clinicians' 'manual' evaluation of the adolescent growth spurt from a collected series of height data, and (2) to construct an automated algorithm to determine the duration of the two phases of growth in health and disease (spurt and final slow growth) independent of clinical pubertal stages. METHODS: One hundred and seventy-four growth curves of normally growing, GH-deficient and Turner's syndrome subjects were presented twice to 2 experienced clinicians. Disagreement between evaluations and clinicians were settled to obtain a 'consensual gold standard' evaluation versus which the algorithm was assessed. Kappa statistics and Bland-Altman analyses were used to evaluate the reliability and agreement of the evaluations. RESULTS: The reliability of 'manual' evaluation of adolescent growth spurt from collected series of height data appeared to be poor. Conversely, the developed algorithm is perfectly reliable and satisfactorily valid. Discrepancies with the clinical consensual gold standard were always fewer than the discrepancies between the expert clinicians, and were observed in similarly difficult curves. CONCLUSION: The developed algorithm may be useful for diverse clinical and biological research applications in children with growth disorders. This study also confirms the value of a comprehensive investigation of growth during adolescence independent of clinical staging.


Assuntos
Algoritmos , Estatura , Crescimento , Nível de Saúde , Adolescente , Feminino , Hormônio do Crescimento Humano/deficiência , Hormônio do Crescimento Humano/uso terapêutico , Humanos , Masculino , Puberdade , Síndrome de Turner/fisiopatologia
15.
Horm Res ; 57 Suppl 2: 71-8, 2002.
Artigo em Inglês | MEDLINE | ID: mdl-12065932

RESUMO

Congenital adrenal hypoplasia (CAH) normally occurs in the neonatal period, with patients presenting with more or less severe salt-wasting syndrome. X-linked CAH has been associated with mutations in the DAX-1 gene, and boys have also been shown to have hypogonadotrophic hypogonadism. Recently, in three unrelated boys, CAH was associated with intrauterine growth retardation (IUGR), metaphyseal dysplasia and genital abnormalities, defining a new association called IMAGe. We now report four additional patients with this association, including the first living female. The four patients belong to two unrelated families (one brother and one sister from each family). These patients have the main clinical characteristics of IMAGe association: IUGR, facial dysmorphy (frontal bossing, broad nasal bridge, low-set ears), short limbs due to metaphyseal dysplasia, and adrenal insufficiency. As these patients are older than the initial three patients, we can also describe additional features: short adult height, normal puberty in boys as well as in the living girl. The boys have hypospadias associated with micropenis. The living girl came to clinical attention at the age of 5 years as a result of a familial survey, and careful questioning revealed that she had been suffering from mild adrenal insufficiency since early childhood. At least one boy has congenital hypotonia due to muscular dystrophy. In conclusion, these four new cases display familial transmission, strongly suggesting Mendelian autosomal recessive inheritance. Adrenal insufficiency may be mild. Hypotonia, described in all the patients, might be related to paucisymptomatic muscular dystrophy, as this condition is clearly heterogeneous varying with regard to severity, associated manifestations and outcome. If this symptom is part of the syndrome, which we cannot assume, it could help to localize the candidate gene.


Assuntos
Insuficiência Adrenal/congênito , Insuficiência Adrenal/genética , Retardo do Crescimento Fetal/complicações , Genes Recessivos/genética , Adolescente , Glândulas Suprarrenais/anormalidades , Insuficiência Adrenal/complicações , Adulto , Biomarcadores/sangue , Estatura/fisiologia , Doenças do Desenvolvimento Ósseo/complicações , Criança , Pré-Escolar , Face/anormalidades , Feminino , Genitália Masculina/anormalidades , Humanos , Lactente , Recém-Nascido , Masculino , Linhagem , Síndrome
16.
Horm Res ; 57 Suppl 2: 88-94, 2002.
Artigo em Inglês | MEDLINE | ID: mdl-12065935

RESUMO

OBJECTIVE: Pubertal growth contributes to 15-18% of adult height. A blunted pubertal peak could contribute to short adult height in short children born with intrauterine growth retardation (IUGR). DESIGN AND METHODS: Pubertal growth, from onset of puberty to final height, was investigated in 75 short IUGR children: 47 were treated with recombinant human growth hormone (GH) (tx) before pubertal onset (mean dose: 0.4 IU/kg/week); 28 were not treated (no-tx). They were compared with 98 normal children. RESULTS: Puberty occurred later in IUGR children than in controls (boys 14.2 +/- 1 years vs. 12.1 +/- 0.8 years; girls 12 +/- 1 years vs. 11.2 +/- 0.8 years; p < 0.0001). In girls, total pubertal growth was similar in all three groups (tx: 19.3 +/- 4.8 cm; no-tx 19.8 +/- 4.9 cm; controls 20.2 +/- 3.9 cm; non-significant). IUGR boys had a reduced pubertal growth (tx: 21.3 +/- 6.2 cm; no-tx: 23.9 +/- 6.1; controls 26.9 +/- 3.9 cm; p < 0.05). The age at puberty onset was the major determinant of pubertal growth amplitude (boys: r = 0.53, p < 0.001; girls: r = 0.45, p < 0.001). IUGR children exhibited little catch-up growth during puberty. CONCLUSIONS: In the present study, we describe a delayed onset of puberty in short children born with IUGR. Moreover, prepubertal GH treatment was associated in boys with a decrease in the amplitude of the pubertal spurt, a finding that should be further evaluated in clinical trials.


Assuntos
Estatura/fisiologia , Retardo do Crescimento Fetal/complicações , Puberdade/fisiologia , Adolescente , Adulto , Análise de Variância , Criança , Pré-Escolar , Feminino , Hormônio do Crescimento/farmacologia , Humanos , Lactente , Estudos Longitudinais , Masculino , Estatística como Assunto , Fatores de Tempo
17.
Hum Reprod Update ; 10(2): 135-47, 2004.
Artigo em Inglês | MEDLINE | ID: mdl-15073143

RESUMO

Precocious puberty results mostly from the precocious activation of the gonadotropic axis. Although the age limits have recently been discussed, most physicians consider that onset of pubertal development before the age of 8 years in a girl or 9 years in a boy warrants at least a clinical and bone age evaluation by a paediatric endocrinologist. The major concern in precocious puberty is the underlying condition, and central nervous system or gonadal neoplasm have to be formally excluded as a first step in the diagnosis. A secondary concern is height, since precocious puberty leads to accelerated growth, accelerated bone maturation and ultimately reduced stature. Precocious puberty is heterogeneous and strict criteria should be used to define it, both in terms of age and in terms of potential for progression. Depot forms of GnRH agonists are now the standard treatment for progressive central precocious puberty and aim at alleviating the clinical symptoms of early pubertal development, their psychological consequences and the effects on growth. Here, we review the consequences of both central and gonadotropin-independent precocious puberty on adult stature and the information available on outcomes using the therapeutic regimens currently available. In girls with progressive precocious puberty, all published evidence indicates a gain of adult height over height predicted before treatment or over untreated historical controls. However, the apparent height gain (derived from the comparison of predicted and actual heights) is very variable, in large part due to the inaccuracy of height prediction methods. In girls with onset of puberty at the lower half of the normal age (8-10 years) distribution, trials using GnRH agonists have given negative results (no benefit of treatment). In boys, precocious puberty is rare and fewer results are available but point in the same direction. The most appropriate time for interrupting the treatment is still controversial. In conclusion, GnRH agonists restore adult height in children when it is compromised by precocious puberty.


Assuntos
Estatura/efeitos dos fármacos , Puberdade Precoce/tratamento farmacológico , Puberdade Precoce/etiologia , Adolescente , Adulto , Criança , Desenvolvimento Infantil/fisiologia , Feminino , Hormônio Liberador de Gonadotropina/agonistas , Gonadotropinas/fisiologia , Hormônio do Crescimento Humano/fisiologia , Humanos , Masculino , Puberdade/fisiologia , Puberdade Precoce/diagnóstico , Valores de Referência , Resultado do Tratamento
18.
Proc Natl Acad Sci U S A ; 100(19): 10972-6, 2003 Sep 16.
Artigo em Inglês | MEDLINE | ID: mdl-12944565

RESUMO

Hypogonadotropic hypogonadism is defined as a deficiency of the pituitary secretion of follicle-stimulating hormone and luteinizing hormone, which results in the impairment of pubertal maturation and of reproductive function. In the absence of pituitary or hypothalamic anatomical lesions and of anosmia (Kallmann syndrome), hypogonadotropic hypogonadism is referred to as isolated hypogonadotropic hypogonadism (IHH). A limited number of IHH cases are due to loss-of-function mutations of the gonadotropin-releasing hormone receptor. To identify additional gene defects leading to IHH, a large consanguineous family with five affected siblings and with a normal gonadotropin-releasing hormone receptor coding sequence was studied. Homozygosity whole-genome mapping allowed the localization of a new locus within the short arm of chromosome 19 (19p13). Sequencing of several genes localized within this region showed that all affected siblings of the family carried a homozygous deletion of 155 nucleotides in the GPR54 gene. This deletion encompassed the splicing acceptor site of intron 4-exon 5 junction and part of exon 5. The deletion was absent or present on only one allele in unaffected family members. GPR54 has been initially identified as an orphan G protein-coupled receptor with 40% homology to galanin receptors. Recently, a 54-aa peptide derived from the KiSS1 protein was identified as a ligand of GPR54. The present study shows that loss of function of GPR54 is a cause of IHH, and it identifies GPR54 and possibly KiSS1 protein-derived peptide as playing a major and previously unsuspected role in the physiology of the gonadotropic axis.


Assuntos
Hipogonadismo/genética , Receptores de Neuropeptídeos/genética , Sequência de Bases , Consanguinidade , Primers do DNA , Feminino , Genótipo , Humanos , Hipogonadismo/fisiopatologia , Masculino , Linhagem , Receptores Acoplados a Proteínas G , Receptores de Kisspeptina-1 , Receptores de Neuropeptídeos/fisiologia
19.
BMJ ; 325(7355): 70, 2002 Jul 13.
Artigo em Inglês | MEDLINE | ID: mdl-12114235

RESUMO

OBJECTIVE: To evaluate the efficacy of recombinant growth hormone for increasing adult height in children treated for idiopathic isolated growth hormone deficiency. DESIGN: Observational follow up study. SETTING: Population based registry. PARTICIPANTS: All 2852 French children diagnosed as having isolated idiopathic growth hormone deficiency whose treatment started between 1987 and 1992 and ended before 1996. MAIN OUTCOME MEASURES: Change in height between the start of treatment and adulthood; classification of patients according to whether treatment was completed as scheduled or stopped early. RESULTS: Adult height was obtained for 2165 (76%) patients. The mean dose of growth hormone at start of treatment was 0.42 IU/kg/week. Height gain was 1.1 (SD 0.9) standard deviation (SD) scores, resulting in an adult height of -1.6 (0.9) SD score (girls, 154 (5) cm; boys, 167 (6) cm). Patients who completed the treatment gained 1.0 (0.7) SD score of height in 3.6 (1.4) years. Patients with treatments stopped early gained 0.6 (0.6) SD score in 2.7 (1.4) years while receiving treatment and a further 0.4 (0.9) SD score after the end of treatment. Most of the variation in height gain was explained by regression towards the mean, patients' characteristics, and delay in starting puberty. Severe growth hormone deficiency was associated with better outcome. Each year of treatment was associated with a gain of 0.2 SD score(1.3 cm). CONCLUSION: The effect of growth hormone is unclear in many patients treated for so called idiopathic isolated growth hormone deficiency. Most of the patients have pubertal delay and a spontaneous growth potential, which must be taken into account when measuring the effect and cost effectiveness of treatments. Growth hormone deficiency should be clearly distinguished from pubertal delay, and criteria should restrict the definition to patients with severely and permanently altered growth hormone secretion as our results support the use of growth hormone in such patients. Long term trials are required for most patients currently treated.


Assuntos
Estatura/efeitos dos fármacos , Transtornos do Crescimento/tratamento farmacológico , Hormônio do Crescimento , Adolescente , Feminino , Crescimento/efeitos dos fármacos , Hormônio do Crescimento/deficiência , Humanos , Masculino , Estudos Prospectivos , Resultado do Tratamento
20.
Eur J Pediatr ; 161(1): 49-59, 2002 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-11808880

RESUMO

UNLABELLED: A collaborative study, supported by the Biomed2 Programme of the European Community, was initiated to optimise the aetiological diagnosis in genetic or gonadal males with intersex disorders, a total of 67 patients with external sexual ambiguity, testicular tissue and/or a XY karyotype. In patients with gonadal dysgenesis or true hermaphroditism, the incidence of vaginal development was 100%, a uterus was present in 60%; uni or bilateral cryptorchidism was seen in nearly all cases of testicular dysgenesis (99%) but in only 57% of true hermaphrodites. Mean serum levels of anti-mullerian hormone and of serum testosterone response to chorionic gonadotropin stimulation were significantly decreased in both conditions, by comparison with patients with unexplained male pseudohermaphroditism or partial androgen insensitivity (PAIS). Mutations in the androgen receptor, 90% within exons 2-8, were detected in patients with PAIS. Clinically, a vaginal pouch was present in 90%, cryptorchidism in 36%. In 52% of cases, no diagnosis could be reached, despite an exhaustive clinical and laboratory work-up, including routine sequencing of exons 2-8 of the androgen receptor. By comparison with PAIS, unexplained male pseudohermaphroditism was characterised by a lower incidence of vaginal pouch (55%) and cryptorchidism (22%) but a high incidence of prematurity/intrauterine growth retardation (30%) or mild malformations (14%). CONCLUSION: reaching an aetiological diagnosis in cases of male intersex is difficult because of the variability of individual cases. Hormonal tests may help to discriminate between partial androgen insensitivity and gonadal dysgenesis/true hermaphroditism but are of less use for differentiating from unexplained male pseudohermaphroditism. Sequencing of exons 2-8 of the androgen receptor after study of testosterone precursors following human chorionic gonadotrophin stimulation is recommended when gonadal dysgenesis and true hermaphroditism can be excluded.


Assuntos
Transtornos do Desenvolvimento Sexual/etiologia , Glicoproteínas , Hormônio Antimülleriano , Gonadotropina Coriônica , Criptorquidismo/genética , Diagnóstico Diferencial , Transtornos do Desenvolvimento Sexual/sangue , Transtornos do Desenvolvimento Sexual/genética , Europa (Continente) , Disgenesia Gonadal/sangue , Disgenesia Gonadal/etiologia , Disgenesia Gonadal/genética , Inibidores do Crescimento/sangue , Humanos , Lactente , Cariotipagem , Masculino , Receptores Androgênicos/genética , Hormônios Testiculares/sangue , Testículo/anormalidades , Testosterona/sangue
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA